Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (Nasdaq: TVTX) will present at three investor conferences in May–June 2026: BofA Securities Health Care (May 13, 2026, 5:20 p.m. ET), Jefferies Global Healthcare (June 3, 2026, 8:45 a.m. ET) and Goldman Sachs 47th Annual Global Healthcare (June 8, 2026, 11:20 a.m. ET).
Live webcasts and replays (available for up to 30 days) will be on Travere’s investor events page: ir.travere.com/events-and-presentations.
Travere Therapeutics (Nasdaq: TVTX) priced an upsized offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032, expected to close May 11, 2026. Travere estimates net proceeds of approximately $460.0 million (or $508.5 million if over-allotment exercised).
About $350.9 million of net proceeds are intended to repurchase approximately $221.4 million aggregate principal of outstanding 2.25% convertible notes due 2029; remaining proceeds for general corporate purposes including commercialization, clinical R&D, capex, and working capital.
Travere (Nasdaq: TVTX)/b) intends to offer
The Notes will be senior unsecured, accrue interest semiannually, and be convertible into cash, common stock, or both. Repurchases depend on negotiations; hedged holders may buy common stock concurrently, potentially affecting market price and effective conversion price. Joint book-runners: J.P. Morgan, Jefferies, Leerink. Registration on Form S-3 filed 08/01/2024.
Travere Therapeutics (Nasdaq: TVTX) reported Q1 2026 results and program updates on May 4, 2026. U.S. net product sales were $124.5 million for Q1 2026 versus $75.9 million in Q1 2025, driven by FILSPARI sales. GAAP net loss was $37.1 million, or $0.40 per share; non-GAAP net income was $4.1 million, or $0.05 per share.
Key operational highlights: FILSPARI U.S. net sales for IgAN were $105.2 million (+88% YoY) with 993 new PSFs in Q1; FDA approved FILSPARI for FSGS on April 13, 2026, expanding the U.S. addressable population to >100,000. Phase 3 HARMONY restarted; first new pegtibatinase patient dosed with topline data expected 2H 2027. Cash and marketable securities totaled $264.7 million as of March 31, 2026.
Travere Therapeutics (Nasdaq: TVTX) will report first quarter 2026 financial results on Monday, May 4, 2026, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a general business update; the live webcast and archived replay will be available via the company Investor Events page for 30 days.
Travere Therapeutics (Nasdaq: TVTX) announced inducement equity grants on April 10, 2026, awarding restricted stock units to five new employees covering an aggregate of 17,420 shares.
The RSUs were granted outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vest over four years with 25% vesting each anniversary, subject to continued service.
Travere Therapeutics (NASDAQ: TVTX) announced full FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
The approval makes FILSPARI the first and only FDA‑approved medicine for FSGS, expands possible reach to >30,000 U.S. patients with non‑nephrotic FSGS and to >100,000 patients including IgAN, and is supported by Phase 3 DUPLEX results showing significant proteinuria and eGFR benefits through Week 108.
Travere Therapeutics (NASDAQ: TVTX) reported fourth-quarter and full-year 2025 results with significant commercial momentum for FILSPARI (sparsentan) and progress in clinical programs. U.S. net product sales were $126.6M in Q4 and $410.5M for full year 2025; FILSPARI sales were $103.3M in Q4 and $322.0M for the year. The company reported a GAAP full-year net loss of $25.5M and non-GAAP net income of $81.1M. The FDA has set a PDUFA target action date of April 13, 2026 for FILSPARI in FSGS. Enrollment resumed in the Phase 3 HARMONY study for pegtibatinase in classical HCU.
Travere Therapeutics (NASDAQ: TVTX) will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
Webcast and dial-in details are available on Travere's Investor page, and an archived recording will be posted for 30 days following the live event.
Travere Therapeutics (NASDAQ: TVTX) disclosed inducement equity grants made on February 10, 2026. The Compensation Committee awarded inducement restricted stock units covering an aggregate of 49,200 shares to ten new employees.
The RSUs were issued outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vest over four years, with 25% vesting each anniversary, subject to continued service.